| 3 Reasons the Market Is Down on Gilead Sciences Apr 18 / MotleyFool.com | Positive Data on AbbVie's HCV Program - Analyst Blog Apr 14 / Zacks.com |
| Glaxo Looking into Misconduct Charges - Analyst Blog Apr 17 / Zacks.com | Is This the Answer to Expensive Hepatitis-C Cures? Apr 14 / MotleyFool.com |
| Roche Meets Sales Estimates in Q1 - Analyst Blog Apr 17 / Zacks.com | Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog Apr 14 / Zacks.com |
| Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead Apr 17 / MotleyFool.com | Benzinga's Top #PreMarket Losers Apr 14 / Benzinga |
| AbbVie Candidate in Pivotal Study - Analyst Blog Apr 17 / Zacks.com | Abbott Labs Progresses with Absorb - Analyst Blog Apr 11 / Zacks.com |
| If This Biotech Drops Much Further I'm Going to Buy It! Apr 17 / MotleyFool.com | Encouraging Data from Bristol-Myers - Analyst Blog Apr 11 / Zacks.com |
| Will Merck & Co. Inc Unseat Biotech's Hottest Drug? Apr 17 / MotleyFool.com | Merck Shouts "Me, Too!" But Will It Matter? Apr 11 / MotleyFool.com |
| Glaxo's Tanzeum Approved in the U.S. - Analyst Blog Apr 16 / Zacks.com | Today's Biotech Stocks to Watch: AbbVie Inc., Enanta Pharmaceuticals Inc. and Gilead ... Apr 11 / MotleyFool.com |
| Is Johnson & Johnson's Dividend Unbeatable? Apr 16 / MotleyFool.com | Merck Up on Encouraging HCV Data - Analyst Blog Apr 10 / Zacks.com |
| Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides Apr 16 / MotleyFool.com | S&P 500 Dividend Aristocrats: Reliably Growing Dividends Apr 10 / MotleyFool.com |
| Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog Apr 16 / Zacks.com | Stunning Spending Growth Prediction for Hepatitis C Apr 10 / MotleyFool.com |
| Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog Apr 15 / Zacks.com | Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co... Apr 10 / MotleyFool.com |
| Repros Completes Enrollment for Androxal Study - Analyst Blog Apr 15 / Zacks.com | Why Enanta Pharmaceuticals, Inc. Should Be on Your Watchlist Apr 09 / MotleyFool.com |
| How Much Has Merck Shaken Up the Hepatitis C Race? Apr 15 / MotleyFool.com | Why Gilead Sciences, AbbVie Inc., and Biogen Idec Are Today's 3 Worst Stocks Apr 08 / MotleyFool.com |
| Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog Apr 15 / Zacks.com | Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog Apr 08 / Zacks.com |
| AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Pat... Apr 15 / Benzinga | FDA Target Date for Gilead's HCV Candidate - Analyst Blog Apr 08 / Zacks.com |
| Hard-to-Cure Patients May Benefit from Merck's HCV Drug - Analyst Blog Apr 14 / Zacks.com | The AACR Annual Meeting May Move These 2 Stocks Apr 07 / MotleyFool.com |
| Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings Apr 14 / Benzinga | |
+0.39 / +0.80%
.
